Anti-amyloid monoclonal antibody therapies, including aducanumab, also have adverse effects, including amyloid-related imaging abnormalities (ARIA), which consist of MRI signal changes of cerebral edema (ARIA-E) and / or microhemorrhage and superficial hemosiderosis (ARIA-H).